Sugi Predict

Sugi Predict / Compounds / SCHEMBL231766

SCHEMBL231766

SCHEMBL231766

Cc1cccc(NC(=O)Nc2ccc(-c3csc4c(-c5ccncc5)cnc(N)c34)cc2)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDR P35968 18/20 1.00
▸ CYP3A4 P08684 2/20 0.88
▸ AURKB Q96GD4 11/20 0.88
▸ AURKA O14965 7/20 0.79
▸ PLK4 O00444 6/20 0.79
▸ ROCK2 O75116 6/20 0.79
▸ NTRK1 P04629 6/20 0.79
▸ LCK P06239 6/20 0.79
▸ CSF1R P07333 6/20 0.79
▸ LYN P07948 6/20 0.79
▸ KIT P10721 6/20 0.79
▸ FGFR1 P11362 6/20 0.79
▸ FLT1 P17948 6/20 0.79
▸ FLT3 P36888 6/20 0.79
▸ BLK P51451 6/20 0.79
▸ NEK2 P51955 6/20 0.79
▸ LIMK1 P53667 6/20 0.79
▸ STK3 Q13188 6/20 0.79
▸ ROCK1 Q13464 6/20 0.79
▸ NTRK2 Q16620 6/20 0.79

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1694775 0.96 KDR (0.97) KDRCYP3A4AURKBAURKAPLK4
SCHEMBL3530051 0.94 KDR (0.91) KDRCYP3A4AURKBAURKAPLK4
SCHEMBL233442 0.94 KDR (1.00) KDRCYP3A4AURKBAURKAPLK4
SCHEMBL3530163 0.94 KDR (1.00) KDRCYP3A4AURKBAURKAPLK4
SCHEMBL3558774 0.93 KDR (0.89) KDRCYP3A4AURKBAURKAPLK4
SCHEMBL3529454 0.93 KDR (1.00) KDRCYP3A4AURKBAURKAPLK4
SCHEMBL3530382 0.93 KDR (0.93) KDRCYP3A4AURKBAURKAPLK4
SCHEMBL3531408 0.93 KDR (1.00) KDRCYP3A4AURKBAURKAPLK4
SCHEMBL3532489 0.93 KDR (0.88) KDRCYP3A4AURKBAURKAPLK4
SCHEMBL3530349 0.92 KDR (0.86) KDRCYP3A4AURKBAURKAPLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120004245-A1 COMPOUNDS FOR THE TREATMENT OF POSTERIOR SEGMENT DISORDERS AND DISEASES ALCON RESEARCH, LTD. (US) 2012-01-05 — — US claimed
JP-4707192-B2 — — 2011-06-22 — — JP claimed
US-20100069371-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBOTT LABORATORIES (US) 2010-03-18 — — US claimed
EP-1648905-B1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBOTT LAB (US) 2008-12-31 — — EP claimed
US-20070155776-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBVIE INC. 2007-07-05 — — US claimed
EP-1648905-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS Abbott Laboratories (US) 2006-04-26 — — EP claimed
US-20050043347-A1 Thienopyridine and furopyridine kinase inhibitors ABBVIE INC. 2005-02-24 — — US claimed
WO-2005010009-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBOTT LABORATORIES (US) 2005-02-03 — — WO claimed
US-8273736-B2 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES (US) 2012-09-25 — — US disclosed
US-20120004245-A1 COMPOUNDS FOR THE TREATMENT OF POSTERIOR SEGMENT DISORDERS AND DISEASES ALCON RESEARCH, LTD. (US) 2012-01-05 — — US disclosed
US-20120004245-A1 COMPOUNDS FOR THE TREATMENT OF POSTERIOR SEGMENT DISORDERS AND DISEASES ALCON RESEARCH, LTD. (US) 2012-01-05 — — US disclosed
US-20120004245-A1 COMPOUNDS FOR THE TREATMENT OF POSTERIOR SEGMENT DISORDERS AND DISEASES ALCON RESEARCH, LTD. (US) 2012-01-05 — — US disclosed
WO-2012003141-A1 COMPOUNDS FOR THE TREATMENT OF POSTERIOR SEGMENT DISORDERS AND DISEASES ALCON RESEARCH, LTD. (US) 2012-01-05 — — WO disclosed
US-7737160-B2 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES INC. (US) 2010-06-15 — — US disclosed
EP-1648905-B1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBOTT LAB (US) 2008-12-31 — — EP disclosed
US-20070155776-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBVIE INC. 2007-07-05 — — US disclosed
US-7202363-B2 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES (US) 2007-04-10 — — US disclosed
US-20050043347-A1 Thienopyridine and furopyridine kinase inhibitors ABBVIE INC. 2005-02-24 — — US disclosed
US-20050026944-A1 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES 2005-02-03 — — US disclosed
US-20050020619-A1 Thienopyridine kinase inhibitors ABBOTT LABORATORIES 2005-01-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120004245-A1 COMPOUNDS FOR THE TREATMENT OF POSTERIOR SEGMENT DISORDERS AND DISEASES ALDH1A2, UACA, VHL KDR 210/4885CYP3A4 4415/4885AURKB 2850/4885
US-20050020619-A1 Thienopyridine kinase inhibitors ABL1, MAP4K2, MAP4K5 KDR 511/4885CYP3A4 2145/4885AURKB 262/4885
US-20050026944-A1 Thienopyridine and furopyridine kinase inhibitors ABL1, ERBB2, LCK KDR 494/4885CYP3A4 1935/4885AURKB 171/4885
US-20050043347-A1 Thienopyridine and furopyridine kinase inhibitors ABL1, ERBB2, LCK KDR 494/4885CYP3A4 1935/4885AURKB 171/4885
US-20100069371-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABL1, ERBB2, LCK KDR 494/4885CYP3A4 1935/4885AURKB 171/4885
US-20070155776-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABL1, ERBB2, LCK KDR 494/4885CYP3A4 1935/4885AURKB 171/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.